Why is Nephros, Inc. ?
1
The company has declared Positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 1.99 MM
- NET SALES(HY) At USD 9.3 MM has Grown at 37.23%
- NET PROFIT(HY) Higher at USD 0.8 MM
2
With ROE of 8.62%, it has a attractive valuation with a 3.83 Price to Book Value
- Over the past year, while the stock has generated a return of 269.48%, its profits have risen by 155.6% ; the PEG ratio of the company is 0.2
3
High Institutional Holdings at 45.28%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 269.48% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you buy?
- Overall Portfolio exposure to Nephros, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Nephros, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Nephros, Inc.
255.04%
1.53
104.16%
S&P 500
13.22%
0.61
20.17%
Quality key factors
Factor
Value
Sales Growth (5y)
9.99%
EBIT Growth (5y)
18.67%
EBIT to Interest (avg)
-2.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
1.55
Tax Ratio
1.50%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
45.28%
ROCE (avg)
2.77%
ROE (avg)
1.72%
Valuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
3.83
EV to EBIT
31.89
EV to EBITDA
31.89
EV to Capital Employed
5.73
EV to Sales
2.06
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
13.86%
ROE (Latest)
8.62%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Technical Movement
22What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 1.99 MM
NET SALES(HY)
At USD 9.3 MM has Grown at 37.23%
NET PROFIT(HY)
Higher at USD 0.8 MM
ROCE(HY)
Highest at 15.14%
RAW MATERIAL COST(Y)
Fallen by -8.3% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -39.93 %
INVENTORY TURNOVER RATIO(HY)
Highest at 2.48 times
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Nephros, Inc.
Net Profit
At USD 0.8 MM has Grown at 273.58%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 9.3 MM has Grown at 37.23%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Profit
Higher at USD 0.8 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 1.99 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at -39.93 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 2.48 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -8.3% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales






